American Society for Metabolic and Bariatric Surgery Position Statement on emerging endosurgical interventions for treatment of obesity

Emerging Technologies and Clinical Issues Committees of the ASMBS

Received January 31, 2009; accepted February 4, 2009

Abstract

The following position statement is issued by the American Society for Metabolic and Bariatric Surgery in response to numerous inquiries made to the Society by patients, physicians, society members, hospitals, health insurance payors, the media, and others regarding emerging endosurgical interventions for treatment of obesity. In this statement, the ASMBS establishes its position on the appropriate steps to be taken before acceptance of new technologies for the treatment of obesity that are based on current knowledge, careful consideration of experts, and published peer-reviewed scientific evidence available at this time. The intent of issuing such a statement is to provide objective information about the process that should be followed in this exciting time of development for endosurgical interventions. The statement is not intended as, and should not be construed as, stating or establishing a local, regional, or national standard of care. The statement will be revised in the future as additional evidence becomes available. (Surg Obes Relat Dis 2009;5:297–298.) © 2009 American Society for Metabolic and Bariatric Surgery. All rights reserved.

Emerging technologies present an opportunity for us to improve patient outcomes and are essential to the evolution of the practice of medicine. Modern day bariatric surgical interventions have developed from a rich history of pioneering surgical innovation, defined recently as “a new procedure that differs from currently accepted local practice, the outcomes of which have not been described, and which may entail risk to the patient” [1]. Decades of outcomes research have led to published standards regarding surgical risk, weight loss outcomes, and the durability of various procedures in long-term follow-up. The result has been the progressive acceptance of bariatric surgery as a mainstream intervention for treatment of the morbidly obese patient. Current ethical standards indicate that innovation requires appropriate oversight “to assess the relative merits and potential adverse consequences” [1–4].

Currently, a number of endoluminal innovations and novel devices and technologies are in various stages of development or application to the elective treatment of obesity, including revisional interventions. The theoretical goals of these therapies include decreasing the invasiveness, risk, and barriers to acceptance of effective treatment of obesity; however, these outcomes cannot be assumed and must be proven. Therefore, the use of novel technologies should be limited to clinical trials done in accordance with the ethical guidelines of the ASMBS and designed to evaluate the risk and efficacy of the intervention. The results of appropriate trials should include the generation of data for risk-benefit analysis, assessments of disability, durability, and the resource use associated with the intervention. An intervention undergoing evaluation should not be judged favorably if the risk/benefit ratio is increased compared with the spectrum of currently accepted surgical procedures [5]. A dramatic reduction in risk might allow for the acceptance of interventions that do not provide traditional durable benefits comparable to currently accepted bariatric procedures [6].

However, it has become clear that clinical trials can be, and have been, manipulated by for-profit entities, including medical device companies, and that this influence on clinical trial results can misrepresent the outcomes of the clinical trial. It is therefore essential to ensure the integrity of clinical trials by recommending the following actions by physicians involved in clinical trials, as recommended by

Reprint requests: Eric J. DeMaria, MD, Chair, ASMBS Clinical Issues Committee, American Society for Metabolic and Bariatric Surgery, 100 Southwest 75th Street, Suite 201, Gainesville, FL 32607
E-mail: eric.demaria@duke.edu
DeAngelis and Fontanarosa [7] and supported in full by the ASMBS in this Position Statement: “For-profit companies that sponsor biomedical research studies should not be solely or primarily involved in collecting and monitoring of data, in conducting the data analysis, and in preparing the manuscript reporting study results. These responsibilities should primarily or solely be performed by academic investigators who are not employed by the company sponsoring the research.” Furthermore, the society supports the registration of all clinical research trials and mandatory reporting of outcomes, whether favorable or not.

If evidence supports the use of a new intervention, several other factors need to be considered before clinical application outside the controlled environment of a clinical trial. Because weight loss interventions are believed to result in better outcomes when the treatment is a part of a comprehensive treatment program, the clinical use of a new intervention should be practiced in the setting of a multidisciplinary treatment team. Nutritional support, experienced nursing care, behavioral medicine specialists, and physicians experienced in the treatment of bariatric patients and their co-morbidities are essential components of such a program. Patients must be educated with honest and informed consent about the procedures to be used, including any lack of knowledge relating to the duration of effectiveness. Training and skill acquisition with the techniques and technology are mandatory before clinical application is undertaken and must include didactic, as well as hands-on, education.

In addition, the ability or availability of physicians and surgeons willing and able to manage potential complications of a specific intervention in morbidly obese patients is advised.

These guidelines are not intended to thwart innovation, but rather to support careful evaluation, develop evidence of effectiveness of new interventions, and protect patients. These guidelines are also not meant to dictate the appropriateness of a given technology within a specific clinical situation, but to highlight the essential components of adequately informing the patient before the intervention and to emphasize the need to study the outcomes of novel therapies.

Emerging endosurgical interventions for treatment of obesity position statement and standard of care

This Position Statement is not intended to provide inflexible rules or requirements of practice and is not intended, nor should it be used, to state or establish a local, regional, or national legal standard of care. Ultimately, there are various appropriate treatment modalities for each patient, and surgeons must use their judgment in selecting from among the different feasible treatment options.

The American Society for Metabolic and Bariatric Surgery cautions against the use of this Position Statement in litigation in which the clinical decisions of a physician are called into question. The ultimate judgment regarding the appropriateness of any specific procedure or course of action must be made by the physician in light of all the circumstances presented. Thus, an approach that differs from the Position Statement, standing alone, does not necessarily imply that the approach was below the standard of care. To the contrary, a conscientious physician may responsibly adopt a course of action different from that set forth in the Position Statement when, in the reasonable judgment of the physician, such a course of action is indicated by the condition of the patient, limitations of the available resources, or advances in knowledge or technology. All that should be expected is that the physician will follow a reasonable course of action based on current knowledge, the available resources, and the needs of the patient to deliver effective and safe medical care. The sole purpose of this Position Statement is to assist practitioners in achieving this objective.

Disclosures

The author claims no commercial associations that might be a conflict of interest in relation to this article.

References